Hydrogel Formulations Incorporating Drug Nanocrystals Enhance the Therapeutic Effect of Rebamipide in a Hamster Model for Oral Mucositis.

endocytosis hydrogel nanocrystals oral mucositis rebamipide

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
09 Jun 2020
Historique:
received: 21 05 2020
revised: 07 06 2020
accepted: 08 06 2020
entrez: 13 6 2020
pubmed: 13 6 2020
medline: 13 6 2020
Statut: epublish

Résumé

A mouthwash formulation of rebamipide (REB) is commonly used to treat oral mucositis; however, this formulation does not provide sufficient treatment or prevention in cases of serious oral mucositis. To improve treatment, we attempted to design a hydrogel incorporating REB nanocrystals (R-NPs gel). The R-NPs gel was prepared by a bead mill method using carbopol hydrogel, methylcellulose and 2-hydroxypropyl-β-cyclodextrin, and another hydrogel incorporating REB microcrystals (R-MPs gel) was prepared following the same protocol but without the bead mill treatment. The REB particle size in the R-MPs gel was 0.15-25 μm, and while the REB particle size was 50-180 nm in the R-NPs gel. Next, we investigated the therapeutic effect of REB nanocrystals on oral mucositis using a hamster model. Almost all of the REB was released as drug nanocrystals from the R-NPs gel, and the REB content in the cheek pouch of hamsters treated with R-NPs gel was significantly higher than that of hamsters treated with R-MPs gel. Further, treatment with REB hydrogels enhanced the healing of oral wounds in the hamsters. REB accumulation in the cheek pouch of hamsters treated with the R-NPs gel was prevented by an inhibitor of clathrin-dependent endocytosis (CME) (40 μM dynasore). In conclusion, we designed an R-NPs gel and found that REB nanocrystals are taken up by tissues through CME, where they provide a persistent effect resulting in an enhancement of oral wound healing.

Identifiants

pubmed: 32527029
pii: pharmaceutics12060532
doi: 10.3390/pharmaceutics12060532
pmc: PMC7356607
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : 18K06769

Références

Support Care Cancer. 2013 Nov;21(11):3179-89
pubmed: 23702538
J Support Oncol. 2004 Nov-Dec;2(6 Suppl 3):3-8
pubmed: 15605918
Ann Oncol. 2003 Apr;14(4):505-7
pubmed: 12649093
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
Lancet Oncol. 2006 Feb;7(2):175-83
pubmed: 16455482
Toxicology. 2014 May 7;319:53-62
pubmed: 24598350
Int J Mol Sci. 2019 Jan 22;20(3):
pubmed: 30678310
J Natl Compr Canc Netw. 2008 Jan;6 Suppl 1:S1-21; quiz S22-4
pubmed: 18289497
Ann Oncol. 2015 Sep;26 Suppl 5:v139-51
pubmed: 26142468
BMC Cancer. 2017 May 5;17(1):314
pubmed: 28476132
Biomed Res Int. 2016;2016:6824719
pubmed: 27965978
Dokl Biol Sci. 2014 Nov;459:330-3
pubmed: 25560208
J Pharmacol Exp Ther. 1999 Jan;288(1):133-8
pubmed: 9862763
Oral Oncol. 2017 Sep;72:179-182
pubmed: 28797456
Dig Dis Sci. 1997 Feb;42(2):319-25
pubmed: 9052513
Dig Dis Sci. 1998 Sep;43(9 Suppl):90S-98S
pubmed: 9753233
Histol Histopathol. 2000 Oct;15(4):1067-76
pubmed: 11005231
Am J Respir Crit Care Med. 2000 Nov;162(5):1905-11
pubmed: 11069833
Dig Dis Sci. 1998 Sep;43(9 Suppl):5S-13S
pubmed: 9753220
Arzneimittelforschung. 1992 Dec;42(12):1462-6
pubmed: 1337697
Biomaterials. 2007 Apr;28(13):2233-43
pubmed: 17261330
J Pharmacol Exp Ther. 2001 Apr;297(1):388-94
pubmed: 11259567
Biol Pharm Bull. 2014;37(7):1109-18
pubmed: 24989003
Pharmaceutics. 2020 Feb 14;12(2):
pubmed: 32075200
Int J Oral Maxillofac Surg. 2012 Feb;41(2):225-38
pubmed: 22071451
J Oral Maxillofac Res. 2012 Jan 01;2(4):e3
pubmed: 24422000
Eur J Pharmacol. 1987 Oct 6;142(1):23-9
pubmed: 3480223
Biochem J. 2008 Jun 15;412(3):415-23
pubmed: 18498251
Dig Dis Sci. 1993 Aug;38(8):1441-9
pubmed: 8393757
Adv Mater. 2009;21:419-424
pubmed: 19606281
Int J Nanomedicine. 2018 Sep 06;13:5215-5229
pubmed: 30233182
Biochim Biophys Acta. 2012 Mar;1818(3):502-11
pubmed: 22155257
Br J Ophthalmol. 2013 Jul;97(7):912-6
pubmed: 23603753
J Pharmacol Exp Ther. 2001 Aug;298(2):485-92
pubmed: 11454909
Small. 2011 Jul 18;7(14):1919-31
pubmed: 21695781
Mol Ther. 2009 Aug;17(8):1411-7
pubmed: 19532143
Arzneimittelforschung. 1993 Mar;43(3):363-6
pubmed: 8387788
Biol Pharm Bull. 2014;37(1):96-104
pubmed: 24389486
Radiother Oncol. 2003 Mar;66(3):253-62
pubmed: 12742264
Cancer. 2004 May 1;100(9 Suppl):1995-2025
pubmed: 15108222
Biol Pharm Bull. 2015;38(12):1918-24
pubmed: 26632183

Auteurs

Noriaki Nagai (N)

Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, Japan.

Ryotaro Seiriki (R)

Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, Japan.

Saori Deguchi (S)

Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, Japan.

Hiroko Otake (H)

Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, Japan.

Noriko Hiramatsu (N)

Laboratory of Molecularbiology and Histochemistry, Fujita Health University Institute of Joint Research, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi 470-1192, Japan.

Hiroshi Sasaki (H)

Department of Ophthalmology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan.

Naoki Yamamoto (N)

Department of Ophthalmology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan.

Classifications MeSH